Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)

Market Cap	5.19B
Revenue (ttm)	1.78B
Net Income (ttm)	29.15M
Shares Out	398.01M
EPS (ttm)	0.07
PE Ratio	178.09
Forward PE	n/a
Dividend	0.05 (0.38%)
Ex-Dividend Date	n/a

Volume	2,165,245
Average Volume	3,411,871
Open	13.13
Previous Close	13.01
Day's Range	12.98 - 13.13
52-Week Range	10.58 - 18.90
Beta	0.72
RSI	47.03
Earnings Date	Apr 25, 2025

About SHE:301246

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, engages in the production and sale of pharmaceutical products in China and internationally. It provides active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, triamine, diacetyl guanine, guanine, and diacetylacyclovir; organic chemical raw materials comprising fluoride salts, glyoxal, and oxalic aci...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 2,075
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301246

Financial Performance

In 2024, SHE:301246's revenue was 1.77 billion, a decrease of -13.83% compared to the previous year's 2.05 billion. Earnings were 51.47 million, a decrease of -40.96%.